Ibnsina Pharma
CASE:ISPH Stock Report
Ibnsina Pharma Balance Sheet Health
Financial Health criteria checks 2/6 Ibnsina Pharma has a total shareholder equity of EGP1.6B and total debt of EGP13.9B, which brings its debt-to-equity ratio to 848.4%. Its total assets and total liabilities are EGP22.1B and EGP20.4B respectively. Ibnsina Pharma's EBIT is EGP1.5B making its interest coverage ratio 1.2. It has cash and short-term investments of EGP1.2B.
Key information
848.4%
Debt to equity ratio
Interest coverage ratio 1.2x Cash ج.م1.21b Equity ج.م1.64b Total liabilities ج.م20.43b Total assets ج.م22.07b
Recent financial health updates
Show all updates
Investor sentiment improves as stock rises 18% Nov 05
New minor risk - Market cap size Oct 30
Price target increased by 31% to ج.م6.34 Oct 16
Investor sentiment improves as stock rises 15% Oct 09
New major risk - Revenue and earnings growth Oct 08
Investor sentiment improves as stock rises 21% Sep 24
New minor risk - Share price stability Sep 23
Investor sentiment improves as stock rises 23% Aug 25
Ibnsina Pharma(CASE:ISPH) dropped from EGX 30 Index Aug 01
First quarter 2024 earnings released: EPS: ج.م0.08 (vs ج.م0.056 in 1Q 2023) May 21
Investor sentiment deteriorates as stock falls 16% Apr 01
Investor sentiment deteriorates as stock falls 15% Mar 12
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Mar 06
Investor sentiment improves as stock rises 18% Feb 07
Price target increased by 16% to ج.م3.43 Jan 01
Investor sentiment improves as stock rises 18% Dec 03
Investor sentiment improves as stock rises 17% Oct 25
Consensus EPS estimates increase by 200% Sep 20
Now 20% undervalued after recent price drop Sep 19
Now 20% undervalued after recent price drop Aug 21
Second quarter 2023 earnings released: EPS: ج.م0.001 (vs ج.م0.016 in 2Q 2022) Aug 14
Investor sentiment deteriorates as stock falls 19% Jul 09
Investor sentiment improves as stock rises 20% Jun 06
Price target decreased by 38% to ج.م2.36 Jun 01
Consensus EPS estimates fall by 50% May 30
First quarter 2023 earnings released: EPS: ج.م0.07 (vs ج.م0.04 in 1Q 2022) May 27
Now 20% undervalued after recent price drop May 01
Investor sentiment improves as stock rises 17% Apr 30
Investor sentiment deteriorates as stock falls 19% Mar 13
Full year 2022 earnings released: EPS: ج.م0.13 (vs ج.م0.22 in FY 2021) Mar 07
Price target decreased by 17% to ج.م3.45 Mar 02
Now 21% undervalued Jan 24
Now 21% undervalued Jan 04
Price target decreased to ج.م4.00 Nov 30
Price target decreased to ج.م3.45 Nov 16
No independent directors Nov 16
Price target decreased to ج.م3.82 Nov 01
Investor sentiment improved over the past week Aug 22
Now 23% undervalued after recent price drop Aug 08
Investor sentiment improved over the past week Aug 05
Investor sentiment improved over the past week Jul 21
Investor sentiment deteriorated over the past week Jul 04
Price target decreased to ج.م5.65 May 31
Ibn Sina Pharma Company (S.A.E) (CASE:ISPH) acquired El Shorouk Hospital for EGP 430 million. May 24
No independent directors Apr 27
Full year 2021 earnings: EPS misses analyst expectations Mar 28
Price target decreased to ج.م6.00 Dec 16
Price target decreased to ج.م6.19 Nov 25
Second quarter 2021 earnings released Aug 21
Price target decreased to ج.م7.32 Aug 16
First quarter 2021 earnings released: EPS ج.م0.04 (vs ج.م0.043 in 1Q 2020) Jun 05
New 90-day low: ج.م4.86 Mar 15
Full year 2020 earnings released: EPS ج.م0.19 (vs ج.م0.28 in FY 2019) Mar 07
Revenue and earnings miss expectations Mar 07
New 90-day low: ج.م5.09 Dec 31
New 90-day low: ج.م5.18 Dec 10
Price target lowered to ج.م8.04 Dec 09
New 90-day low: ج.م5.77 Nov 19
Price target lowered to ج.م9.00 Nov 18
Ibn Sina Pharma (S.A.E) (CASE:ISPH) signed an agreement to acquire 75% stake in 3elagi Tech. Nov 10
New 90-day low: ج.م5.93 Oct 15
New 90-day low: ج.م7.27 Sep 23
New 90-day low - ج.م7.63 Aug 31
Earnings released Aug 16
Price target lowered to ج.م11.62 Jul 26
New 90-day low - ج.م7.73 Jul 23
Financial Position Analysis
Short Term Liabilities: ISPH's short term assets (EGP19.2B) exceed its short term liabilities (EGP19.2B).
Long Term Liabilities: ISPH's short term assets (EGP19.2B) exceed its long term liabilities (EGP1.2B).
Debt to Equity History and Analysis
Debt Level: ISPH's net debt to equity ratio (774.5%) is considered high .
Reducing Debt: ISPH's debt to equity ratio has increased from 157.1% to 848.4% over the past 5 years.
Debt Coverage: ISPH's debt is not well covered by operating cash flow (0.3%).
Interest Coverage: ISPH's interest payments on its debt are not well covered by EBIT (1.2x coverage).
Discover healthy companies Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}